Skip to main content
. Author manuscript; available in PMC: 2012 Aug 1.
Published in final edited form as: J Immunol. 2011 Jun 22;187(3):1113–1119. doi: 10.4049/jimmunol.1100056

Figure 1. Disparate allograft outcome following PD1 and PDL1 blockade in the single MHC class II-mismatched transplant model.

Figure 1

(A) bm12 cardiac grafts transplanted into B6 WT recipients had a median survival time of greater than 56 days. Anti-PD1 mAbs treatment had similar allograft survival times to untreated group; however, allograft rejection was remarkably accelerated when recipients were treated with dual-blockade MIH6 anti-PDL1 mAb. (B) Bm12 cardiac grafts transplanted into a PD1-deficient recipients had a median survival time of greater than 56 days. When PD1KO recipients were treated with anti-PDL1 mAb, (MIH6) allograft rejection was remarkably accelerated despite PD1 deficiency. N= 6 for each group.